Andromeda Metals Limited (ASX: ADN) is positioned for a potential market re-rating as its flagship Great White Project in South Australia moves into a construction-ready stage. A new initiation report by East Coast Research has set a 12-month target price of A$0.054 per share, representing an implied upside of about 348% from the current level of A$0.012.
The Great White Project is underpinned by an ore reserve of 15.1Mt, providing a projected mine life of 28 years. Development will be rolled out in three stages, with the initial Stage 1A+ targeting annual production of around 100,000 wet metric tonnes before ramping up to 330,000t in later phases.
Funding has been partially secured through a A$75M debt facility from Merricks Capital, which has received credit approval. Key long-lead plant items have already been ordered, and binding offtake agreements covering the Stage 1A+ output are in place with partners in Europe, China and Japan, including Traxys, IberoClays, Foshan Gaoming, and Plantan Yamada.
The kaolin from the project is high purity with very low iron content of about 0.5% Fe₂O₃, powder brightness of 84% and fired brightness above 90%. Halloysite content of 11 to 14% adds to its premium value in global ceramics markets such as tiles, porcelain, glazes, and decorative wares. Laboratory trials have also confirmed potential for high-purity alumina production at 99.9985%, adding a longer-term growth option.
On financials, the report estimates a post-tax base-case net present value of A$205M and a bull case of A$271M, with life-of-mine revenues between A$4.9B and A$5.9B. Equity valuation ranges from A$0.045 to A$0.062 per share, with the target midpoint of A$0.054.
Key milestones that could drive re-rating include the final investment decision on Stage 1A+, the closing of a full funding package, and progress on production ramp-up. Risks remain around pricing, currency movements, cost inflation and execution, but the report argues that Andromeda Metals is well placed to deliver substantial shareholder value as it moves towards first production.
For more information, visit www.andromet.com.au
To read more articles like this, please visit www.theassay.com/news
